Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PPM1B | O75688 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.49 |
| ▸ | LGMN | Q99538 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666182 | 0.88 | MAPT (0.45) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL17869504 | 0.87 | MAPT (0.45) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL464391 | 0.85 | ALDH1A1 (0.73) | MAPTALDH1A1TSHRCYP3A4CYP2D6 | |
| SCHEMBL237380 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL8891623 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2375356 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL4221 | 0.84 | — | — | |
| SCHEMBL5360827 | 0.84 | PPM1B (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL18040053 | 0.83 | MAPT (0.53) | MAPTALDH1A1LGMNCYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL28788727 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 982 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | claimed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | claimed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | claimed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20250221996-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-07-10 | — | — | US | disclosed |
| EP-4551574-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2025-05-14 | — | — | EP | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119487028-A | Heterocyclic compounds, compositions thereof and methods of treatment therewith | 百济神州有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-1995003285-A1 | 1,5-BENZODIAZEPINE DERIVATIVES USEFUL AS CCK OR GASTRIN ANTAGONISTS | GLAXO SPA (IT) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995003284-A1 | 1,5-BENZODIAZEPINE DERIVATIVES USEFUL AS CCK OR GASTRIN ANTAGONISTS | GLAXO SPA (IT) | 1995-02-02 | — | — | WO | disclosed |
| US-5373018-A | Antagonist to excitory amino acids on N-methyl aspartic acid receptor complex, theraputically effective in treatment of central nervous system disorder | GLAXO S.P.A. (IT) | 1994-12-13 | — | — | US | disclosed |
| US-5242943-A | Administering as beta adrenoceptor blocking agents | Louis, William J. (AU) | 1993-09-07 | — | — | US | disclosed |
| US-5051445-A | Cardiovascular disorders such as antiarrhythmia or cardiotonic agents, adrenergic blocking agents | Louis, William J. (AU) | 1991-09-24 | — | — | US | disclosed |
| EP-0177515-B1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Louis, William John (AU) | 1989-05-31 | — | — | EP | disclosed |
| EP-0177515-A4 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-09-23 | — | — | EP | disclosed |
| EP-0177515-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-04-16 | — | — | EP | disclosed |
| WO-1985004403-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ LTD. (CH) | 1985-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | MAPT 3244/4885ALDH1A1 1629/4885PPM1B 1165/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MAPT 389/4885ALDH1A1 4061/4885PPM1B 2543/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | MAPT 4330/4885ALDH1A1 1195/4885PPM1B 3124/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | MAPT 383/4885ALDH1A1 4050/4885PPM1B 2536/4885 |
| US-20250221996-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, HRAS | MAPT 4040/4885ALDH1A1 1351/4885PPM1B 1220/4885 |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | MAPT 4293/4885ALDH1A1 484/4885PPM1B 2394/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MAPT 389/4885ALDH1A1 4061/4885PPM1B 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.